CoChat
Sign Up
Cited by 232Acute Kidney Injury ResearchClinical Nutrition and GastroenterologyChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial

Doig, Gordon S., Simpson, Fiona, Bellomo, Rinaldo, Heighes, Philippa T., Sweetman, Elizabeth A., Chesher, Douglas, Pollock, Carol, Davies, Andrew, Botha, John, Harrigan, Peter, Reade, Michael C.·2015·Intensive Care Medicine
DOI 10.1007/s00134-015-3827-9
Open this paper in CoChat — free account

Abstract

Importance Acute kidney injury (AKI) is characterized by severe loss of glomerular filtration rate (GFR) and is associated with a prolonged intensive care unit (ICU) stay and increased risk of death. No interventions have yet been shown to prevent AKI or preserve GFR in critically ill patients. Evidence from mammalian physiology and small clinical trials suggests higher amino acid intake may protect the kidney from ischemic insults and thus may preserve GFR during critical illness. Objective To determine whether amino acid therapy, achieved through daily intravenous (IV) supplementation with standard amino acids, preserves kidney function in critically ill patients. Design, setting, and participants Multicenter, phase II, randomized clinical trial conducted between December 2010 and February 2013 in the ICUs of 16 community and tertiary hospitals in Australia and New Zealand. Participants were adult critically ill patients expected to remain in the study ICU for longer than 2 days. Interventions Random allocation to receive a daily supplement of up to 100 g of IV amino acids or standard care. Main outcomes and measures Duration of renal dysfunction (primary outcome); estimated GFR (eGFR) derived from creatinine; eGFR derived from cystatin C; urinary output; renal replacement therapy (RRT) use; fluid balance and other measures of renal function. Results 474 patients were enrolled and randomized (235 to standard care, 239 to IV amino acid therapy). At time of enrollment, patients allocated to receive amino acid therapy had higher APACHE II scores (20.2 ± 6.8 vs. 21.7 ± 7.6, P = 0.02) and more patients had pre-existing renal dysfunction (29/235 vs. 44/239, P = 0.07). Duration of renal dysfunction after enrollment did not differ between groups (mean difference 0.21 AKI days per 10 patient ICU days, 95 % CI -0.27 to 1.04, P = 0.45). Amino acid therapy significantly improved eGFR (treatment group × time interaction, P = 0.004), with an early peak difference of 7.7 mL/min/1.73 m(2) (95 % CI 1.0-14.5 mL/min/1.73 m(2), P = 0.02) on study day 4. Daily urine output was also significantly increased (+300 mL/day, 95 % CI 145-455 mL, P = 0.0002). There was a trend towards increased RRT use in patients receiving amino acid therapy (13/235 vs. 25/239, P = 0.062); however, this trend was not present after controlling for baseline imbalance (P = 0.21). Conclusion and relevance Treatment with a daily IV supplement of standard amino acids did not alter our primary outcome, duration of renal dysfunction. Trial registration anzctr.org.au Identifier: ACTRN12609001015235.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00134-015-3827-9

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Bernard GR, Doig GS, Hudson LD, Lemeshow S, Marshall JC, Russel J et al (1995) Quantification of organ failure for clinical trials and clinical practice. Am J Respir Crit Care Med 151:A323
  2. Doig GS, Simpson F, Sweetman EA, Heighes PT, on behalf of the Nephro-Protective Trial Management Committee (2013) Statistical analysis plan for a multi-centre randomised controlled trial: nephro-protective effects of L-amino acids in critically ill patients. EvidenceBased.net, Sydney

Cited by

Sorted by citations

See all 232

Related

See all

Metadata

Authors
Doig, G. S., Simpson, F., Bellomo, R., Heighes, P. T., Sweetman, E. A., Chesher, D., Pollock, C., Davies, A., Botha, J., Harrigan, P., & Reade, M. C.
Affiliations
  • The University of Sydney (AU)
  • Monash University (AU)
  • John Hunter Hospital (AU)
  • The University of Queensland (AU)
Corresponding author
Doig, Gordon S.
ORCID
Venue
Intensive Care Medicine
Publisher
Springer Science and Business Media LLC
Published
2015-04-30
Volume
41
Issue
7
Pages
1197-1208
ISSN
  • 0342-4642 (ISSN-L)
  • 1432-1238
DOI
10.1007/s00134-015-3827-9
OpenAlex
W2010536286
Cited by
232
References
40
Citations by year
2026: 11 · 2025: 24 · 2024: 34 · 2023: 17 · 2022: 16 · 2021: 20 · 2020: 18 · 2019: 28 · 2018: 30 · 2017: 21 · 2016: 9 · 2015: 4
FWCI
18.49
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Intensive Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
National Health and Medical Research Council (632614)
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
intravenous amino acids, acute kidney injury, critically ill patients, renal function preservation, estimated glomerular filtration rate, cystatin C, renal replacement therapy, fluid balance, urine output, intensive care unit, APACHE II score, dietary supplementation, ICU length of stay
MeSH terms
Aged, Amino Acids, Creatinine, Female, Glomerular Filtration Rate, Humans, Intensive Care Units, Male, Middle Aged, Critical Illness, Cystatin C, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review